
In 2 pivotal phase 3 studies, all 5 readers hit sensitivity and specificity targets for florquinitau F 18 tau PET, including in patients with early symptomatic Alzheimer disease.
We invite you to reflect on your diagnostic understanding of topics presented this year.
Best of Psychiatric Times in 2015.



